Generation Bio (GBIO) Competitors $1.11 +0.04 (+3.74%) (As of 05:22 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends GBIO vs. CCCC, FDMT, IMMP, BNTC, CMPS, FHTX, ACIU, AMLX, LFCR, and ITOSShould you be buying Generation Bio stock or one of its competitors? The main competitors of Generation Bio include C4 Therapeutics (CCCC), 4D Molecular Therapeutics (FDMT), Immutep (IMMP), Benitec Biopharma (BNTC), COMPASS Pathways (CMPS), Foghorn Therapeutics (FHTX), AC Immune (ACIU), Amylyx Pharmaceuticals (AMLX), Lifecore Biomedical (LFCR), and iTeos Therapeutics (ITOS). These companies are all part of the "pharmaceutical products" industry. Generation Bio vs. C4 Therapeutics 4D Molecular Therapeutics Immutep Benitec Biopharma COMPASS Pathways Foghorn Therapeutics AC Immune Amylyx Pharmaceuticals Lifecore Biomedical iTeos Therapeutics C4 Therapeutics (NASDAQ:CCCC) and Generation Bio (NASDAQ:GBIO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, community ranking, risk, media sentiment and valuation. Which has stronger valuation & earnings, CCCC or GBIO? Generation Bio has lower revenue, but higher earnings than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than Generation Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioC4 Therapeutics$33.67M8.11-$132.49M-$1.70-2.28Generation Bio$18.58M3.85-$126.61M-$2.19-0.49 Is CCCC or GBIO more profitable? C4 Therapeutics has a net margin of -313.35% compared to Generation Bio's net margin of -782.86%. C4 Therapeutics' return on equity of -42.45% beat Generation Bio's return on equity.Company Net Margins Return on Equity Return on Assets C4 Therapeutics-313.35% -42.45% -27.55% Generation Bio -782.86%-104.85%-49.54% Does the media favor CCCC or GBIO? In the previous week, C4 Therapeutics had 7 more articles in the media than Generation Bio. MarketBeat recorded 8 mentions for C4 Therapeutics and 1 mentions for Generation Bio. C4 Therapeutics' average media sentiment score of 0.85 beat Generation Bio's score of 0.00 indicating that C4 Therapeutics is being referred to more favorably in the media. Company Overall Sentiment C4 Therapeutics Positive Generation Bio Neutral Which has more risk & volatility, CCCC or GBIO? C4 Therapeutics has a beta of 2.92, indicating that its stock price is 192% more volatile than the S&P 500. Comparatively, Generation Bio has a beta of 2.66, indicating that its stock price is 166% more volatile than the S&P 500. Does the MarketBeat Community believe in CCCC or GBIO? Generation Bio received 15 more outperform votes than C4 Therapeutics when rated by MarketBeat users. Likewise, 70.00% of users gave Generation Bio an outperform vote while only 39.13% of users gave C4 Therapeutics an outperform vote. CompanyUnderperformOutperformC4 TherapeuticsOutperform Votes2739.13% Underperform Votes4260.87% Generation BioOutperform Votes4270.00% Underperform Votes1830.00% Do analysts rate CCCC or GBIO? C4 Therapeutics presently has a consensus price target of $10.67, indicating a potential upside of 175.62%. Generation Bio has a consensus price target of $7.50, indicating a potential upside of 600.93%. Given Generation Bio's stronger consensus rating and higher probable upside, analysts plainly believe Generation Bio is more favorable than C4 Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score C4 Therapeutics 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Generation Bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders believe in CCCC or GBIO? 78.8% of C4 Therapeutics shares are owned by institutional investors. Comparatively, 95.2% of Generation Bio shares are owned by institutional investors. 8.6% of C4 Therapeutics shares are owned by insiders. Comparatively, 21.1% of Generation Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryC4 Therapeutics beats Generation Bio on 10 of the 18 factors compared between the two stocks. Ad Crypto 101 MediaGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which is why I'm recommending ONE coin to all investors right now. Click here to check it out now Get Generation Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for GBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GBIO vs. The Competition Export to ExcelMetricGeneration BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$71.47M$6.69B$5.22B$9.25BDividend YieldN/A2.98%5.12%4.28%P/E Ratio-0.4910.6087.8017.22Price / Sales3.85204.011,161.56122.20Price / CashN/A57.1543.3837.82Price / Book0.355.154.834.93Net Income-$126.61M$151.58M$120.83M$225.51M7 Day Performance-0.93%3.08%2.44%3.90%1 Month Performance-25.69%-4.25%17.51%1.68%1 Year Performance-42.16%7.42%28.57%16.09% Generation Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GBIOGeneration Bio2.6515 of 5 stars$1.11+3.7%$7.50+575.7%-44.0%$74.14M$18.58M-0.51150Short Interest ↑CCCCC4 Therapeutics2.172 of 5 stars$4.28-2.3%$10.00+133.6%-13.2%$302.12M$33.67M-2.58150Short Interest ↑News CoverageFDMT4D Molecular Therapeutics3.0223 of 5 stars$6.53+0.5%$42.13+545.1%-71.9%$301.87M$17,000.00-2.28201IMMPImmutep1.222 of 5 stars$2.07-5.0%$8.50+310.6%-16.3%$301.10M$5.14M0.002,021News CoverageBNTCBenitec Biopharma3.7738 of 5 stars$12.76+8.4%$24.43+91.4%+247.7%$296.29M$80,000.000.0020Positive NewsCMPSCOMPASS Pathways2.4553 of 5 stars$4.29+1.7%$33.60+683.2%-53.9%$293.53MN/A-1.92120News CoveragePositive NewsFHTXFoghorn Therapeutics2.1085 of 5 stars$5.27-0.6%$16.00+203.6%-25.3%$292.98M$25.52M-2.63120Short Interest ↑High Trading VolumeACIUAC Immune2.7876 of 5 stars$2.95flat$12.00+306.8%-38.1%$291.87M$16.48M-6.41140Positive NewsAMLXAmylyx Pharmaceuticals3.8494 of 5 stars$4.18+1.5%$7.33+75.4%-72.4%$286.53M$196.49M-1.08200Short Interest ↑LFCRLifecore Biomedical2.9776 of 5 stars$7.71+1.3%$10.00+29.7%+20.3%$283.94M$128.44M97.50690ITOSiTeos Therapeutics3.4852 of 5 stars$7.72+0.5%$25.25+227.1%-31.5%$282.04M$35M-2.4490 Related Companies and Tools Related Companies CCCC Alternatives FDMT Alternatives IMMP Alternatives BNTC Alternatives CMPS Alternatives FHTX Alternatives ACIU Alternatives AMLX Alternatives LFCR Alternatives ITOS Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GBIO) was last updated on 12/26/2024 by MarketBeat.com Staff From Our PartnersIs Jeff Bezos Crowning the Next Nvidia?It doesn't matter what you think about AI... Because Jeff Bezos's massive load-up on one tiny tech company ...InvestorPlace | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored“AI Killer” 10x More Powerful Than ChatGPTElon Musk may be about to “kill” the world’s most powerful AI. Very few people are talking about the one AI...Paradigm Press | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredElon Musk could help pay for your retirementElon Musk is the richest man in the world... And he's pouring trillions into a unique investment.Brownstone Research | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Generation Bio Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Generation Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
